Montemagno Christopher, Pagès Gilles
Département de Biologie Médicale, Centre Scientifique de Monaco, 98000 Monaco, Monaco.
Institute for Research on Cancer and Aging of Nice, Centre Antoine Lacassagne, CNRS UMR 7284 and INSERM U1081, University Côte d'Azur, 06200 Nice, France.
Cancers (Basel). 2020 Mar 29;12(4):821. doi: 10.3390/cancers12040821.
Breast cancer is the most common malignancy in women throughout the world. Metastatic dissemination to vital organs is the leading cause of breast cancer-related deaths. The treatment of metastases is mainly based on the primary tumor characteristics. However, breast cancer metastases exhibit high heterogeneity leading to different prognosis and therapeutic responses. Getting access to phenotype of metastases would allow better management of patients. The advent of theranostics in nuclear medicine has opened new opportunities for the diagnosis and treatment of cancer patients. The aim of this review is to provide an overview of current knowledge and future directions in nuclear medicine for therapeutic management of metastatic breast cancer patients.
乳腺癌是全球女性中最常见的恶性肿瘤。向重要器官的转移扩散是乳腺癌相关死亡的主要原因。转移瘤的治疗主要基于原发肿瘤的特征。然而,乳腺癌转移瘤表现出高度异质性,导致不同的预后和治疗反应。了解转移瘤的表型将有助于更好地管理患者。核医学中治疗诊断学的出现为癌症患者的诊断和治疗开辟了新机会。本综述的目的是概述核医学在转移性乳腺癌患者治疗管理方面的当前知识和未来方向。